Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus

被引:191
作者
Lapteva, Larissa
Nowak, Miroslawa
Yarboro, Cheryl H.
Takada, Kazuki
Roebuck-Spencer, Tresa
Weickert, Thomas
Bleiberg, Joseph
Rosenstein, Donald
Pao, Maryland
Patronas, Nicholas
Steele, Sonya
Manzano, Melissa
van der Veen, Jan Willem C.
Lipsky, Peter E.
Marenco, Stefano
Wesley, Robert
Volpe, Bruce
Diamond, Betty
Illei, Gabor G.
机构
[1] Natl Inst Dent & Craniofacial Res, NIH, Sjogrens Syndrome Clin, Bethesda, MD 20892 USA
[2] Natl Rehabil Hosp, Washington, DC USA
[3] Cornell Univ, Weill Coll Med, New York, NY USA
[4] Columbia Univ, Coll Phys & Surg, New York, NY USA
来源
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 08期
关键词
GLUTAMATE RECEPTORS; REVISED CRITERIA; BRAIN-INJURY; IMPAIRMENT; PREVALENCE; CLASSIFICATION; SPECTROSCOPY; PREDICTORS; KETAMINE; IMMUNITY;
D O I
10.1002/art.22031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To assess the association of cognitive dysfunction and depression with serum antibodies to N-methyl-D-aspartate (NMDA) receptor (anti-NR2) and analyze clinical and neuroimaging correlates in patients with systemic lupus erythematosus (SLE). Methods. Sixty patients underwent neurocognitive assessment, evaluation for depression with the Beck Depression Inventory II (BDI-II) and psychiatric interview (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV] criteria), brain magnetic resonance imaging, and proton magnetic resonance spectroscopy imaging (H-1-MRSI). Cognition was assessed in 5 domains: memory, attention/executive, visuospatial, motor, and psychomotor, and adjusted to each individual's best level of prior cognitive functioning estimated from the reading subtest of the Wide Range Achievement Test-3 (WRAT-3). Serum anti-NR2 antibodies were measured by enzyme-linked immunosorbent assay using a pentapeptide from the human NMDA receptor. Results. Cognitive dysfunction was found in 28 of 60 patients (mild in 8, moderate in 20) before adjustment for WRAT-3 and in 35 of 60 patients (mild in 15, moderate in 11, and severe in 9) after adjustment for WRAT-3. The changes were most pronounced in the memory and visuospatial domains. There was no significant association between anti-NR2 antibody levels and cognition. On H-1-MRSI, patients with moderate or severe cognitive dysfunction had significantly higher choline:creatine ratios in the dorsolateral prefrontal cortex and the white matter, compared with patients with mild or absent cognitive dysfunction. Anti-NR2 antibodies were significantly correlated with BDI scores; patients with BDI-II scores of >= 14 had higher serum levels of anti-NR2 antibodies (P = 0.005, 95% confidence interval 0.83, 4.31), and there was a trend toward higher anti-NR2 antibody levels among patients who fulfilled the DSM-IV criteria for major depression. Conclusion. Serum anti-NR2 antibodies are associated with depressive mood but not with cognitive dysfunction in SLE at a given time point. Larger longitudinal studies are needed to address the possible association between anti-NR2 antibodies and depression in SLE.
引用
收藏
页码:2505 / 2514
页数:10
相关论文
共 57 条
[1]   Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities [J].
Ainiala, H ;
Hietaharju, A ;
Dastidar, P ;
Loukkola, J ;
Lehtimäki, T ;
Peltola, J ;
Korpela, M ;
Heinonen, T ;
Nikkari, ST .
ARTHRITIS AND RHEUMATISM, 2004, 50 (03) :858-865
[2]   TREATMENT OF IMPAIRED CEREBRAL FUNCTION IN PSYCHOGERIATRIC PATIENTS WITH MEMANTINE - RESULTS OF A PHASE-II DOUBLE-BLIND-STUDY [J].
AMBROZI, L ;
DANIELCZYK, W .
PHARMACOPSYCHIATRY, 1988, 21 (03) :144-146
[3]  
Arnold DL, 2000, NEUROIMAG CLIN N AM, V10, P789
[4]  
Beck A.T., 1996, BECK DEPRESSION INVE, DOI DOI 10.1037/T00742-000
[5]   Antidepressant effects of ketamine in depressed patients [J].
Berman, RM ;
Cappiello, A ;
Anand, A ;
Oren, DA ;
Heninger, GR ;
Charney, DS ;
Krystal, JH .
BIOLOGICAL PSYCHIATRY, 2000, 47 (04) :351-354
[6]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[7]   THE PROTON NMR-SPECTRUM IN ACUTE EAE - THE SIGNIFICANCE OF THE CHANGE IN THE CHO-CR RATIO [J].
BRENNER, RE ;
MUNRO, PMG ;
WILLIAMS, SCR ;
BELL, JD ;
BARKER, GJ ;
HAWKINS, CP ;
LANDON, DN ;
MCDONALD, WI .
MAGNETIC RESONANCE IN MEDICINE, 1993, 29 (06) :737-745
[8]   Neuropsychiatric syndromes in lupus -: Prevalence using standarized definitions [J].
Brey, RL ;
Holliday, SI ;
Saklad, AR ;
Navarrete, MG ;
Hermosillo-Romo, D ;
Stallworth, CL ;
Valdez, CR ;
Escalante, A ;
del Rincón, I ;
Gronseth, G ;
Rhine, CB ;
Padilla, P ;
McGlasson, D .
NEUROLOGY, 2002, 58 (08) :1214-1220
[9]  
Brooks WM, 1999, J RHEUMATOL, V26, P81
[10]   PREVALENCE OF COGNITIVE IMPAIRMENT IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
CARBOTTE, RM ;
DENBURG, SD ;
DENBURG, JA .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1986, 174 (06) :357-364